恒瑞创新药恒优达获批上市，PNH罕见病迎来一线治疗新选择

作为一家专注研发、生产及推广高品质药物的创新型国际化制药企业，恒瑞医药始终坚持创新与国际化战略。公司研发投入占营业收入比重连续多年保持在25%以上，位居行业前列，并以此构建起多元化且稳健的创新产品管线。截至目前，在中国获批27款1类新药、6款2类新药 ...
The Manila Times

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people ...
lupus.bmj

DIA proteomics of FFPE renal biopsies reveals two molecular subtypes of lupus nephritis and identifies APOL1 as candidate biomarker for stratification

Introduction Lupus nephritis (LN) exhibits substantial clinical and pathological heterogeneity. We aimed to define proteomics-based molecular subtypes of LN and identify candidate biomarkers for ...

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Operator: Good morning, everyone, and welcome to the Annexon Business Update Call. [Operator Instructions] As a reminder, ...